Can glucagon-like peptide-1 receptor agonists cause an elevation in bilirubin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

GLP-1 Receptor Agonists and Bilirubin Elevation

GLP-1 receptor agonists do not directly cause bilirubin elevation, but they are associated with increased risk of gallbladder and biliary diseases (cholecystitis, cholelithiasis, cholangitis), which can secondarily lead to conjugated hyperbilirubinemia through biliary obstruction.

Primary Mechanism: Biliary Disease, Not Direct Hepatotoxicity

The available evidence demonstrates that GLP-1 receptor agonists increase the risk of gallbladder and biliary pathology rather than causing direct hepatocellular injury or bilirubin metabolism disorders:

  • Meta-analysis of 76 RCTs (103,371 patients) showed GLP-1 RA use was associated with increased risk of cholelithiasis (RR 1.27), cholecystitis (RR 1.36), and biliary disease (RR 1.55) 1
  • The risk was dose-dependent (higher doses: RR 1.56 vs. lower doses: RR 0.99) and duration-dependent (longer use: RR 1.40 vs. shorter use: RR 0.79) 1
  • Risk was particularly elevated when used for weight loss (RR 2.29) compared to diabetes management (RR 1.27) 1

Real-World Evidence Confirms the Association

A Taiwanese nationwide cohort study comparing GLP-1 RAs to SGLT2 inhibitors found:

  • Increased risk of composite biliary-related diseases (HR 1.27) 2
  • Specifically elevated risk for acute cholecystitis/cholecystectomy (HR 1.29) and choledocholithiasis (HR 1.74) 2
  • Liraglutide showed elevated risk, but dulaglutide did not 2
  • Risk was more evident in patients >60 years, women, and after 120 days of treatment 2

A UK population-based study (71,369 patients) confirmed GLP-1 analogues were associated with increased bile duct and gallbladder disease (adjusted HR 1.79) and cholecystectomy (adjusted HR 2.08) compared to dual oral antidiabetic therapy 3.

When Bilirubin Elevation Occurs: Secondary to Obstruction

If bilirubin elevation occurs in a patient on GLP-1 receptor agonists, the pattern will typically be:

  • Conjugated (direct) hyperbilirubinemia with elevated alkaline phosphatase and GGT, indicating cholestasis 4
  • This represents biliary obstruction from choledocholithiasis, cholecystitis, or cholangitis—not primary hepatocellular injury
  • The guideline framework indicates that conjugated hyperbilirubinemia with elevated ALP suggests extrahepatic or intrahepatic cholestasis requiring biliary imaging 4

Hepatoprotective Effects vs. Biliary Complications

Importantly, a large Scandinavian cohort study (91,479 GLP-1 RA users) showed GLP-1 receptor agonists were associated with reduced risk of serious liver events (HR 0.85), specifically compensated and decompensated cirrhosis, suggesting hepatoprotective effects 5. This further supports that any bilirubin elevation is not from direct hepatotoxicity but from mechanical biliary obstruction.

Clinical Approach to Elevated Bilirubin in GLP-1 RA Users

When encountering elevated bilirubin in a patient taking GLP-1 receptor agonists:

  1. Determine if conjugated or unconjugated: Measure direct and total bilirubin 4
  2. If conjugated with elevated ALP/GGT: Suspect biliary obstruction
  3. First-line imaging: Abdominal ultrasound to evaluate for cholelithiasis, cholecystitis, or bile duct dilation 4
  4. If obstruction confirmed: Consider MRCP or ERCP for further evaluation and management
  5. Rule out Gilbert syndrome: If unconjugated hyperbilirubinemia without other abnormalities 4

Key Caveats

  • The absolute risk of biliary disease remains relatively low (6.1 per 1000 person-years for GLP-1 RAs vs. 3.3 for dual oral agents) 3
  • Not all GLP-1 RAs carry equal risk: Liraglutide showed elevated risk while dulaglutide did not in one cohort 2
  • Patients should be counseled about gastrointestinal symptoms (nausea, vomiting) which are common but also about right upper quadrant pain suggesting biliary disease 6, 7
  • The biliary risk should be weighed against cardiovascular and metabolic benefits, particularly in high-risk patients 8

References

4
Guideline

acr appropriateness criteria® abnormal liver function tests.

Journal of the American College of Radiology, 2023

6
Guideline

standards of medical care for type 2 diabetes in china 2019.

Diabetes/Metabolism Research and Reviews, 2019

7
Guideline

clinical and investigative endocrinology and diabetes.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2018

Related Questions

Can glucagon‑like peptide‑1 receptor agonists (e.g., liraglutide, semaglutide, dulaglutide) worsen pre‑existing gallstones?
Should a patient on a GLP-1 (Glucagon-like peptide-1) receptor agonist stop the medication if they develop gallstones?
Are gallstones a contraindication for Glucagon-like peptide-1 (GLP-1) receptor agonists?
What are the guidelines for using Glucagon-like peptide-1 (GLP-1) receptor agonists, such as exenatide (Byetta), liraglutide (Victoza), or dulaglutide (Trulicity), during pregnancy?
What are the risks of gallbladder disease associated with Ozempic (semaglutide)?
What over-the-counter cough medication is safe for an adult with elevated hepatic enzymes?
What are the indications for oral silymarin tablets?
What is the link between hypertension, acute respiratory distress syndrome (ARDS), and a patent foramen ovale (PFO) in adult ICU patients?
In a 20‑year‑old who suffered head trauma yesterday and now has clear fluid draining from the ear, could this indicate a temporal‑bone fracture with cerebrospinal fluid leak, and what urgent management is required?
What are the major neurologic adverse effects of tranexamic acid?
What are the indications for Caripill tablets?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.